论文部分内容阅读
目的:观察清肺合剂联合化疗治疗晚期非小细胞肺癌(NSCLC)临床疗效。方法:选择2008年1月-2010年1月间收治的经确诊的初治晚期NSCLC患者210例,分别入清肺合剂联合GP方案(治疗组)104例和单纯GP方案化疗(对照组)106例,入组患者至少接受2个周期以上的化疗。结果:入组的210例患者均可评价疗效,治疗1年后随访210例,治疗组99例,对照组98例,失访13例。治疗组和对照组总有效率分别是26.92%和19.81%,中位生存期为15.7个月和14.8个月,1年生存率为63.64%和55.10%。两组差异无显著性(P>0.05)。治疗后,治疗组在KPS评分、临床症状改善及化疗不良反应方面与对照组比较差异有统计学意义(P<0.05)。结论:清肺合剂联合化疗治疗晚期非小细胞肺癌,在改善患者的临床症状,提高患者的生活质量,减轻化疗的不良反应等方面具有临床意义。
Objective: To observe the clinical effects of Qingfei mixture combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: A total of 210 patients with newly diagnosed advanced NSCLC who were admitted between January 2008 and January 2010 were enrolled in this study. One hundred and forty-four patients were treated with combination therapy of pulmonary surfactant and GP (treatment group) and 104 Cases, patients in the group received at least 2 cycles of chemotherapy. Results: A total of 210 patients were enrolled in this study. 210 cases were followed up after one year, 99 cases in the treatment group and 98 cases in the control group, and 13 cases were lost to follow-up. The total effective rate of treatment group and control group were 26.92% and 19.81%, respectively. The median survival time was 15.7 months and 14.8 months. The 1-year survival rates were 63.64% and 55.10% respectively. There was no significant difference between the two groups (P> 0.05). After treatment, the treatment group had significant difference (P <0.05) in KPS score, clinical symptom improvement and adverse reaction of chemotherapy compared with the control group. Conclusion: Qingfei Mixture combined with chemotherapy for advanced non-small cell lung cancer has clinical significance in improving clinical symptoms, improving patients’ quality of life and alleviating the adverse reactions of chemotherapy.